Globeflex Capital L P Acquires New Holdings in Collegium Pharmaceutical, Inc. $COLL

Globeflex Capital L P bought a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 52,911 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,915,000. Globeflex Capital L P owned about 0.16% of Collegium Pharmaceutical as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Collegium Pharmaceutical by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock valued at $569,000 after purchasing an additional 825 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after purchasing an additional 461,914 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Collegium Pharmaceutical by 7.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock valued at $2,120,000 after buying an additional 4,625 shares during the period. Jane Street Group LLC raised its holdings in Collegium Pharmaceutical by 218.7% in the 1st quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock valued at $3,926,000 after buying an additional 90,255 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Collegium Pharmaceutical by 3.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company’s stock valued at $2,131,000 after buying an additional 2,592 shares during the last quarter.

Collegium Pharmaceutical Stock Up 0.9%

Shares of NASDAQ:COLL opened at $27.35 on Tuesday. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03. Collegium Pharmaceutical, Inc. has a 52-week low of $25.47 and a 52-week high of $50.79. The business’s 50 day simple moving average is $33.53 and its two-hundred day simple moving average is $35.56. The firm has a market cap of $890.52 million, a P/E ratio of 22.06 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, beating the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The firm had revenue of $199.88 million during the quarter, compared to the consensus estimate of $199.62 million. During the same quarter in the previous year, the company posted $1.68 earnings per share. The company’s quarterly revenue was up 6.3% on a year-over-year basis. As a group, research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

COLL has been the topic of a number of research reports. Weiss Ratings lowered shares of Collegium Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Piper Sandler reaffirmed a “neutral” rating and set a $43.00 target price (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday, August 7th. Wall Street Zen lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $51.00.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.